Light-Controllable PROTACs for Temporospatial Control of Protein Degradation

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation

PROteolysis-TArgeting Chimeras (PROTACs) is an emerging and promising approach to target intracellular proteins for ubiquitination-mediated degradation, including those so-called undruggable protein targets, such as transcriptional factors and scaffold proteins. To date, plenty of PROTACs have been...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Jing Liu, Yunhua Peng, Wenyi Wei
Natura:	Articolo
Lingua:	English
Pubblicazione:	Frontiers Media S.A. 2021-07-01
Serie:	Frontiers in Cell and Developmental Biology
Soggetti:	ubiquitin E3 ligase PROTAC tumorigenesis light controllable
Accesso online:	https://www.frontiersin.org/articles/10.3389/fcell.2021.678077/full

Documenti analoghi

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
di: Si-Min Qi, et al.
Pubblicazione: (2021-05-01)

PROTAC<sup>®</sup> technology and potential for its application in infection control
di: M. A. Zakharova, et al.
Pubblicazione: (2024-07-01)

Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species
di: Yoshitaka Ogawa, et al.
Pubblicazione: (2024-01-01)

Targeted Protein Degradation: Principles and Applications of the Proteasome
di: Yosup Kim, et al.
Pubblicazione: (2023-07-01)

E3 ligase ligand optimization of Clinical PROTACs
di: Hanrui Jiang, et al.
Pubblicazione: (2023-01-01)

Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
di: Marcin Cieślak, et al.
Pubblicazione: (2023-03-01)

Editorial: Application of PROTACs as a Novel Strategy for Drug Discovery
di: Hany S. Ibrahim, et al.
Pubblicazione: (2021-07-01)

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
di: Mikihiko Naito, et al.
Pubblicazione: (2019-12-01)

Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation
di: Laura Márquez-Cantudo, et al.
Pubblicazione: (2021-09-01)

A Toolbox for the Generation of Chemical Probes for Baculovirus IAP Repeat Containing Proteins
di: Martin P. Schwalm, et al.
Pubblicazione: (2022-05-01)

Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues
di: Marta Pichlak, et al.
Pubblicazione: (2023-12-01)

Unraveling the Engagement of Kinases to CRBN Through a Shared Structural Motif to Optimize PROTACs Efficacy
di: Serena Rosignoli, et al.
Pubblicazione: (2025-02-01)

Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
di: Danishuddin, et al.
Pubblicazione: (2023-11-01)

PROTACs: A novel strategy for cancer drug discovery and development
di: Xin Han, et al.
Pubblicazione: (2023-06-01)

Antiviral PROTACs: Opportunity borne with challenge
di: Jinsen Liang, et al.
Pubblicazione: (2023-06-01)

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
di: Xin Han, et al.
Pubblicazione: (2022-05-01)

Identification of suitable target/E3 ligase pairs for PROTAC development using a rapamycin-induced proximity assay (RiPA)
di: Bikash Adhikari, et al.
Pubblicazione: (2024-12-01)

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
di: Ming He, et al.
Pubblicazione: (2021-06-01)

PROTACs in gastrointestinal cancers
di: Yu Chen, et al.
Pubblicazione: (2022-12-01)

MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
di: Mengyang Chang, et al.
Pubblicazione: (2022-08-01)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
di: Sinan Ma, et al.
Pubblicazione: (2022-07-01)

Ubiquitin-proteasome system: a potential participant and therapeutic target in antiphospholipid syndrome
di: He Wang, et al.
Pubblicazione: (2025-02-01)

The roles of protein ubiquitination in tumorigenesis and targeted drug discovery in lung cancer
di: Zhen Ye, et al.
Pubblicazione: (2023-09-01)

Ubiquitin recruiting chimera: more than just a PROTAC
di: Tatyana A. Grigoreva, et al.
Pubblicazione: (2024-07-01)

Targeting Cullin-RING E3 Ligases for Radiosensitization: From NEDDylation Inhibition to PROTACs
di: Shuhua Zheng, et al.
Pubblicazione: (2020-08-01)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
di: Yonghan He, et al.
Pubblicazione: (2020-07-01)

Discovery of E3 Ligase Ligands for Target Protein Degradation
di: Jaeseok Lee, et al.
Pubblicazione: (2022-10-01)

Dysregulation of ubiquitination modification in renal cell carcinoma
di: Hongjie You, et al.
Pubblicazione: (2024-12-01)

Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities
di: Aiman B. Awan, et al.
Pubblicazione: (2025-01-01)

PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
di: Hiroyuki Inuzuka, et al.
Pubblicazione: (2022-01-01)

E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies
di: Maoyu Wang, et al.
Pubblicazione: (2023-07-01)

A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1
di: Youqin Xu, et al.
Pubblicazione: (2019-02-01)

E3 ubiquitin ligases: styles, structures and functions
di: Quan Yang, et al.
Pubblicazione: (2021-07-01)

Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis
di: Xiu Yin, et al.
Pubblicazione: (2022-07-01)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
di: Alberto Ocaña, et al.
Pubblicazione: (2020-09-01)

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
di: Siqi Wang, et al.
Pubblicazione: (2024-01-01)

PROTACs targeting epigenetic proteins
di: Chao Zhang, et al.
Pubblicazione: (2023-12-01)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
di: Arvind Negi, et al.
Pubblicazione: (2022-11-01)

Computational strategies for PROTAC drug discovery
di: Jia Wu, et al.
Pubblicazione: (2023-02-01)

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
di: Sandra Kuemper, et al.
Pubblicazione: (2024-04-01)